Then, the T2DM mice model was established, and intrathecal injection of 10 μg si-TBK1 (siRNA3) or caspase-1 inhibitor Ac-YVAD-cmk 10 nmol per mouse was given every two days for three weeks. This evidence concerns the gene TBK1 and type 2 diabetes mellitus.